All patients
stage IIIa stage IIIb stage IIIc
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - (neo)adjuvant (NA), anti-CTLA-4 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 238, 2017 0.87 [0.66; 1.14]
EORTC 18071, 2015 0.72 [0.58; 0.89]
0.77 [0.65 ; 0.93 ] CheckMate 238, 2017, EORTC 18071, 2015 2 14% 1,857 low not evaluable deaths (OS) (extension)detailed results EORTC 18071, 2015 0.73 [0.64; 0.83]
0.73 [0.64 ; 0.83 ] EORTC 18071, 2015 1 0% 951 NA not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
EORTC 18071, 2015 0.76 [0.63; 0.91]
0.75 [0.65 ; 0.87 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,686 low not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
EORTC 18071, 2015 0.75 [0.63; 0.89]
0.73 [0.65 ; 0.83 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,857 low not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
EORTC 18071, 2015 0.75 [0.63; 0.89]
0.72 [0.62 ; 0.82 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,857 low not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
EORTC 18071, 2015 7.53 [3.17; 17.90]
1.93 [0.13 ; 28.07 ] CheckMate 238, 2017, EORTC 18071, 2015 2 94% 1,850 low not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
EORTC 18071, 2015 0.11 [0.08; 0.17]
0.18 [0.08 ; 0.43 ] CheckMate 238, 2017, EORTC 18071, 2015 2 93% 1,850 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
0.15 [0.10 ; 0.21 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
0.11 [0.07 ; 0.18 ] CheckMate 238, 2017 1 0% 905 NA not evaluable TRAE (any grade)detailed results CheckMate 238, 2017 0.25 [0.15; 0.43]
EORTC 18071, 2015 14.40 [10.07; 20.60]
1.91 [0.04 ; 100.98 ] CheckMate 238, 2017, EORTC 18071, 2015 2 99% 1,850 low not evaluable TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.20 [0.14; 0.27]
EORTC 18071, 2015 25.27 [14.14; 45.18]
2.22 [0.02 ; 257.63 ] CheckMate 238, 2017, EORTC 18071, 2015 2 100% 1,850 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
EORTC 18071, 2015 10.16 [0.55; 186.52]
1.66 [0.04 ; 62.62 ] CheckMate 238, 2017, EORTC 18071, 2015 2 66% 1,850 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 238, 2017 0.12 [0.08; 0.17]
EORTC 18071, 2015 21.35 [13.41; 33.97]
1.58 [0.01 ; 259.15 ] CheckMate 238, 2017, EORTC 18071, 2015 2 100% 1,850 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.09 [0.05; 0.15]
0.09 [0.05 ; 0.15 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.02; 14.96]
0.50 [0.02 ; 14.96 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
0.50 [0.09 ; 2.74 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
0.50 [0.05 ; 5.53 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.03; 2.24]
0.25 [0.03 ; 2.24 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Colitis TRAE (grade 3-4)detailed results EORTC 18071, 2015 39.14 [5.34; 286.74]
39.14 [5.34 ; 286.74 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.15 [0.07; 0.34]
EORTC 18071, 2015 25.54 [6.16; 105.87]
1.89 [0.01 ; 290.44 ] CheckMate 238, 2017, EORTC 18071, 2015 2 97% 1,850 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results EORTC 18071, 2015 42.70 [5.84; 312.15]
42.70 [5.84 ; 312.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
0.50 [0.09 ; 2.74 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
EORTC 18071, 2015 22.61 [8.20; 62.34]
1.49 [0.01 ; 299.98 ] CheckMate 238, 2017, EORTC 18071, 2015 2 99% 1,850 low not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.14 [0.02; 1.15]
0.14 [0.02 ; 1.15 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
EORTC 18071, 2015 57.44 [7.90; 417.44]
2.71 [0.01 ; 929.94 ] CheckMate 238, 2017, EORTC 18071, 2015 2 97% 1,850 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 1.00 [0.06; 16.07]
1.00 [0.06 ; 16.07 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.04; 0.81]
EORTC 18071, 2015 44.19 [2.67; 732.31]
2.46 [0.01 ; 542.19 ] CheckMate 238, 2017, EORTC 18071, 2015 2 91% 1,850 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
0.50 [0.05 ; 5.53 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.02; 0.44]
0.10 [0.02 ; 0.44 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.07; 0.48]
0.18 [0.07 ; 0.48 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.05 [0.00; 0.95]
0.05 [0.00 ; 0.95 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results EORTC 18071, 2015 18.45 [1.07; 319.15]
18.45 [1.07 ; 319.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.01; 1.82]
0.10 [0.01 ; 1.82 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
0.25 [0.01 ; 5.55 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.35 [0.13; 0.98]
EORTC 18071, 2015 10.16 [0.55; 186.52]
1.42 [0.05 ; 36.59 ] CheckMate 238, 2017, EORTC 18071, 2015 2 78% 1,850 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
0.12 [0.01 ; 2.36 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
EORTC 18071, 2015 42.00 [2.53; 697.02]
2.31 [0.01 ; 487.21 ] CheckMate 238, 2017, EORTC 18071, 2015 2 92% 1,850 low not evaluable Abdominal pain AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.17]
0.04 [0.01 ; 0.17 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Cough AE (grade 3-4)detailed results Out of scale EORTC 18071, 2015 0.01 [0.00; 0.15]
0.01 [0.00 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Decreased appetite AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.01; 0.46]
0.06 [0.01 ; 0.46 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Diarrhoea AE (grade 3-4)detailed results EORTC 18071, 2015 0.26 [0.18; 0.37]
0.26 [0.18 ; 0.37 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Fatigue AE (grade 3-4)detailed results EORTC 18071, 2015 0.05 [0.03; 0.10]
0.05 [0.03 ; 0.10 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Headache AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.11]
0.04 [0.01 ; 0.11 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results EORTC 18071, 2015 0.80 [0.45; 1.45]
0.80 [0.45 ; 1.45 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increased ALT AE (grade 3-4)detailed results EORTC 18071, 2015 0.97 [0.55; 1.70]
0.97 [0.55 ; 1.70 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nausea AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pruritus AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.07; 0.26]
0.14 [0.07 ; 0.26 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pyrexia AE (grade 3-4)detailed results EORTC 18071, 2015 0.21 [0.08; 0.56]
0.21 [0.08 ; 0.56 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Rash AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.03; 0.15]
0.06 [0.03 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Vomiting AE (grade 3-4)detailed results EORTC 18071, 2015 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Weight decreased AE (grade 3-4)detailed results EORTC 18071, 2015 0.02 [0.00; 0.16]
0.02 [0.00 ; 0.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-28 00:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 284,70,235
- treatments: 504,850,329,558,579,549,868,502,741,556